Data from a China-based study indicate that Akeso Pharmaceuticals’ bispecific antibody ivonescimab targeting PD-1 and VEGF achieved a statistically significant overall survival benefit when combined with chemotherapy in patients with non-small cell lung cancer whose disease progressed after EGFR-targeted therapies. This promising outcome may enhance regulatory prospects and treatment options in a heavily burdened oncology indication.